Effects of an alpha-4 integrin inhibitor on restenosis in a new porcine model combining endothelial denudation and stent placement

PLoS ONE

Volumn 5, Issue 12, 2010, Pages

  Braun, Anne ^a   Dofiles, Lilibeth ^b   Rousselle, Serge ^c   Guerrero, Luis ^a   Gunther, Jane ^b   Yednock, Ted ^b   Stricker Krongrad, Alain ^a   Messersmith, Elizabeth ^b  

^a CHARLES RIVER LABORATORIES   (United States)

^b ELAN PHARMACEUTICALS   (United States)

^c Alizee Pathology LLC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA4 INTEGRIN INHIBITOR; CARDIOVASCULAR AGENT; ELN 457946; UNCLASSIFIED DRUG; ALPHA4 INTEGRIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY DISEASE; ARTERY INTIMA; ARTERY WALL; ARTICLE; BARE METAL STENT; COMMON CAROTID ARTERY; CONTROLLED STUDY; CORONARY STENT; DOMESTIC PIG; DRUG BLOOD LEVEL; ENDOTHELIUM CELL; HISTOPATHOLOGY; ILIAC ARTERY; IN-STENT RESTENOSIS; INFLAMMATION; LEFT ANTERIOR DESCENDING CORONARY ARTERY; MALE; NONHUMAN; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; TREATMENT DURATION; TREATMENT RESPONSE; ANIMAL; CHEMISTRY; CYTOLOGY; DISEASE MODEL; DRUG DESIGN; INTIMA; METABOLISM; METHODOLOGY; PATHOLOGY; RESTENOSIS; STENT; SWINE; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME;

SUIDAE; SUS; SUS SCROFA DOMESTICA;

ANGIOPLASTY, BALLOON, CORONARY; ANIMALS; CORONARY RESTENOSIS; DISEASE MODELS, ANIMAL; DRUG DESIGN; ENDOTHELIAL CELLS; INFLAMMATION; INTEGRIN ALPHA4; MALE; STENTS; SWINE; TREATMENT OUTCOME; TUNICA INTIMA;

EID: 78650779268     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0014314     Document Type: Article

References (37)

1. Virmani R, Farb A (1999) Pathology of in-stent restenosis. Curr Opin Lipidol 10(6): 499-506.
2. Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, et al. (2003) SIRIUS Investigators. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 349(14): 1315-1323.
3. Stone GW, Ellis SG, Cox DA, Hermiller J, O'Shaughnessy C, et al. (2004) TAXUS-IV Investigators. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 350(3): 221-231.
4. Nakazawa G, Finn AV, John MC, Kolodgie FD, Virmani R (2007) The significance of preclinical evaluation of sirolimus-, paclitaxel-, and zotarolimuseluting stents. Am J Cardiol 100(8B): 36M-44M.
5. Schwartz RS, Chronos AN, Virmani R (2004) Preclinical restenosis models and drug-eluting stents: Still important, still much to learn. J Am Coll Cardiol 44: 1373-1385.
6. Touchard AG, Schwartz RS (2006) Preclinical restenosis models: challenges and successes. Toxicol Pathol 34(1): 11-18.
7. Schwartz RS, Edelman ER, Carter A, Chronos N, Rogers C, et al. (2002) Consensus Committee. Drug-eluting stents in preclinical studies: recommended evaluation from a consensus group. Circulation 106(14): 1867-1873.
8. Perkins LE (2010) Preclinical models of restenosis and their application to the evaluation of drug eluting stent systems. Vet Pathol 47(1): 58-76.
9. Grinstead WC, Rodgers GP, Mazur W, French BA, Cromeens D, et al. (1994) Comparison of three porcine restenosis models: the relative importance of hypercholesterolemia, endothelial abrasion, and stenting. Coron Artery Dis 5(5): 425-434.
10. Busnelli M, Froio A, Bacci ML, Giunti M, Cerrito MG, et al. (2009) Pathogenetic role of hypercholesterolemia in a novel preclinical model of vascular injury in pigs. Atherosclerosis 207(2): 384-390.
11. Virmani R, Kolodgie FD, Farb A, Lafont A (2003) Drug eluting stents: are human and animal studies comparable? Heart 89(2): 133-138.
12. Welt FGP, Rogers C (2002) Inflammation and Restenosis in the Stent Era. Arterioscler Thromb Vasc Biol 22: 1769-1776.
13. Davis A, Fischer J, Ley KF, Sarembock IJ (2003) The role of inflammation in vascular injury and repair. J of Thromb Haemost 1: 1699-1709.
14. Welt FGP, Edelman ER, Simon DI, Rogers C (1996) Neutrophil, not macrophage, infiltration precedes neointimal thickening in balloon-injured arteries. Arterioscler Thromb Vasc Biol 20: 2553-2558.
15. Hood JD, Cheresh DA (2002) Role of integrins in cell invasion and migration. Nat Rev Cancer 2(2): 91-100.
16. Barringhaus KG, Phillips JW, Thatte JS, Sanders JM, Czarnik AC, et al. (2004) a4b1 Integrin (VLA-1) Blockade attenuates both early and late leukocyte recruitment and neointimal growth following carotid injury in apolipoprotein E (-/-) Mice. J Vasc Res 41: 252-260.
17. Kling D, Fingerle J, Harlan JM, Lobb RR, Lang F (1995) Mononuclear leukocytes invade rabbit arterial intima during thickening formation via CD18 and VLA-4 dependent mechanisms and stimulate smooth muscle migration. Circ Res 77: 1121-1128.
18. Huo Y, Hafezi-Moghadam A, Ley KF (2000) Role of vascular cell adhesion molecule-1 and fibronectin connecting segment-1 in monocyte rolling and adhesion on early atherosclerotic lesion. Circ Res 87: 153-159.
19. Labinaz M, Hoffert C, Pels K, Aggarwal S, Pepinsky RB, et al. (2000) Infusion of an antialpha-4 integrin antibody is associated with less adventitial formation after balloon injury of porcine coronary arteries. Can J Cardiol 16(2): 187-196.
20. Schwartz RS, Edelman E, Virmani R, Carter A, Granada JF, et al. (2008) Drugeluting stents in preclinical studies: Updated consensus recommendations for preclinical evaluation. Circ Cardiovasc Intervent 1: 143-153.
21. Schwartz RS, Edwards WD, Bailey KR, Camrud AR, Jorgenson MA, et al. (1994) Differential neointimal response to coronary artery injury in pigs and dogs. Implications for restenosis models. Arterioscler Thromb 14(3): 395-400.
22. Fitzgerald PJ, Takagi A, Moore MP, Hayase M, Kolodgie FD, et al. (2001) Intravascular sonotherapy decreases neointimal hyperplasia after stent implantation in swine. Circulation 103(14): 1828-1831.
23. Burke SE, Lubbers NL, Chen YW, Hsieh GC, Mollison KW, et al. (1999) Neointimal formation after balloon-induced vascular injury in Yucatan minipigs is reduced by oral rapamycin. J Cardiovasc Pharmacol 33(6): 829-835.
24. Ward MR, Agrotis A, Kanellakis P, Hall J, Jennings G, et al. (2002) Tranilast prevents activation of transforming growth factor-beta system, leukocyte accumulation, and neointimal growth in porcine coronary arteries after stenting. Arterioscler Thromb Vasc Biol 22(6): 940-948.
25. Ishiwata S, Verheye S, Robinson KA, Salame MY, de Leon H, et al. (2000) Inhibition of neointima formation by tranilast in pig coronary arteries after balloon angioplasty and stent implantation. J Am Coll Cardiol 35(5): 1331-1337.
26. Rodriguez AE (2009) Emerging drugs for coronary restenosis: the role of systemic oral agents the in stent era. Expert Opin Emerg Drugs 14(4): 561-576.
27. Brito L, Amiji M (2007) Nanoparticulate carriers for the treatment of coronary restenosis. Int J Nanomedicine 2(2): 143-161.
28. Danenberg HD, Fishbein I, Epstein H, Waltenberger J, Moerman E, et al. (2003) Systemic depletion of macrophages by liposomal bisphosphonates reduces neointimal formation following balloon-injury in the rat carotid artery. J Cardiovasc Pharmacol 42(5): 671-679.
29. Danenberg HD, Golomb G, Groothuis A, Gao J, Epstein H, et al. (2003) Liposomal alendronate inhibits systemic innate immunity and reduces in-stent neointimal hyperplasia in rabbits. Circulation 108(22): 2798-2804.
30. Levitzki A (2005) PDGF receptor kinase inhibitors for the treatment of restenosis. Cardiovasc Res 65(3): 581-586.
31. Charles R, Sandirasegarane L, Yun J, Bourbon N, Wilson R, et al. (2000) Ceramide-coated balloon catheters limit neointimal hyperplasia after stretch injury in carotid arteries. Circ Res 87(4): 282-288.
32. Chen YD, Lu YL, Jin ZN, Yuan F, LüsZ (2006) A prospective randomized antiplatelet trial of cilostazol versus clopidogrel in patients with bare metal stent. Chin Med J (Engl) 119(5): 360-366.
33. Ward MR, Kanellakis P, Ramsey D, Jennings GL, Bobik A (2000) Response to balloon injury is vascular bed specific: a consequence of de novo vessel structure? Atherosclerosis 151(2): 407-414.
34. Steinberg DH, Gaglia MA, Jr., Pinto Slottow TL, Roy P, Bonello L, et al. (2009) Outcome differences with the use of drug-eluting stents for the treatment of instent restenosis of bare-metal stents versus drug-eluting stents. Am J Cardiol 103(4): 491-495.
35. Whan Lee C, Kim SH, Suh J, Park DW, Lee SH, et al. (2008) Long-term clinical outcomes after sirolimus-eluting stent implantation for treatment of restenosis within bare-metal versus drug-eluting stents. Catheter Cardiovasc Interv 71(5): 594-598.
36. Nebeker JR, Virmani R, Bennett CL, Hoffman JM, Samore MH, et al. (2006) Hypersensitivity cases associated with drug-eluting coronary stents: a review of available cases from the Research on Adverse Drug Events and Reports (RADAR) project. J Am Coll Cardiol 47(1): 175-181.
37. Virmani R, Farb A, Guagliumi G, Kolodgie FD (2004) Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: should we be cautious? Circulation 109(6): 701-705.